<p>NT PHARMA (01011.HK) announced its performance for the fiscal year 2025, with revenue of RMB 24.158 million, a year-on-year decrease of 36.4%. The loss narrowed from RMB 53.357 million in the same period of 2024 to RMB 26.041 million; the loss per share is 4.22 cents. No final dividend is declared</p>

159837

510660

588130

<p>NT PHARMA announced its 2025 annual performance, with revenue of RMB 24.158 million, a year-on-year decrease of 36.4%. The loss narrowed from RMB 53.357 million in the same period of 2024 to RMB 26.041 million; the loss per share is 4.22 cents. No final dividend is declared</p>

AASTOCKS

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

NT PHARMA

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

"Performance" NT PHARMA's annual loss narrowed to 26.041 million RMB, no dividend distribution